Share Price and Basic Stock Data
Last Updated: January 29, 2026, 6:28 pm
| PEG Ratio | 0.94 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Kingfa Science & Technology (India) Ltd operates in the plastics sector, focusing on the production of various plastic products. The company’s revenue trajectory has shown a robust upward trend, with reported sales rising from ₹1,048 Cr in FY 2022 to ₹1,404 Cr in FY 2023. This growth continued into FY 2024, where sales stood at ₹1,488 Cr, and further increased to ₹1,745 Cr in FY 2025. The trailing twelve months (TTM) sales reached ₹1,838 Cr, indicating a sustained demand for its products. Quarterly sales figures also reflect this trend, with the latest reported sales of ₹394 Cr in Dec 2023 and ₹404 Cr in Mar 2024. This consistent increase in sales demonstrates the company’s strong market position and effective operational strategies in a competitive industry. The company’s operational performance is underscored by its ability to maintain a steady sales growth rate, which is critical for capturing market share in the plastics sector.
Profitability and Efficiency Metrics
Kingfa’s profitability metrics indicate a strong operational performance, with an operating profit margin (OPM) of 13% as of FY 2025. The operating profit rose significantly from ₹82 Cr in FY 2022 to ₹225 Cr in FY 2025. Additionally, the company reported a net profit of ₹157 Cr for FY 2025, up from ₹81 Cr in FY 2023, showcasing a solid growth trajectory. The return on equity (ROE) stood at 23.2%, while the return on capital employed (ROCE) was reported at an impressive 30.6%, highlighting efficient use of capital. The interest coverage ratio of 35.23x further emphasizes the company’s ability to meet its interest obligations comfortably, a critical indicator of financial health. However, the operating profit margin has exhibited fluctuations, with a high of 15% in FY 2023 and a dip to 10% in Q4 FY 2024, suggesting a need for careful cost management in maintaining profitability amid rising expenses.
Balance Sheet Strength and Financial Ratios
The balance sheet of Kingfa Science & Technology reflects a solid financial foundation, with total assets reported at ₹1,156 Cr and total liabilities at ₹1,156 Cr as of FY 2025. The company’s reserves have grown substantially, reaching ₹1,281 Cr by Sep 2025, indicating a strong retention of earnings. Borrowings are minimal, reported at ₹19 Cr, resulting in a total debt-to-equity ratio of 0.05, which is low compared to typical industry standards. The current ratio of 2.02 indicates a strong liquidity position, suggesting that the company can easily cover its short-term obligations. Additionally, Kingfa’s book value per share increased to ₹601.63 in FY 2025 from ₹384.78 in FY 2023, reflecting strong retained earnings and shareholder value creation. This financial stability positions the company favorably against competitors, enabling it to invest in growth opportunities while maintaining a conservative debt profile.
Shareholding Pattern and Investor Confidence
As of Sep 2025, Kingfa’s shareholding pattern indicates a strong promoter holding of 67.02%, which demonstrates significant insider confidence in the company’s direction. The presence of foreign institutional investors (FIIs) at 7.78% and domestic institutional investors (DIIs) at 8.75% further underscores a diversified ownership structure, which is essential for stability and investor confidence. The public shareholding stood at 16.45%, reflecting a healthy interest from retail investors. Over the reporting periods, there has been a gradual decline in promoter holding from 74.99% in Mar 2025, which might indicate a strategic move to enhance liquidity and attract institutional participation. The increase in the number of shareholders from 12,158 in Mar 2025 to 12,610 by Sep 2025 suggests growing interest and confidence in the company’s growth prospects, which could be beneficial in enhancing market perception and share performance.
Outlook, Risks, and Final Insight
Looking ahead, Kingfa Science & Technology is well-positioned to capitalize on its growth trajectory in the plastics sector, supported by strong revenue growth and profitability metrics. However, risks remain, including potential fluctuations in raw material prices, which could impact margins. Additionally, the company’s ability to manage operational costs will be critical in maintaining profitability amid competitive pressures. The ongoing transition in the shareholding pattern raises questions about potential dilution of control, but it could also enhance liquidity and attract broader investment interest. If the company successfully navigates these challenges and continues to innovate in product offerings, it could sustain its growth momentum. Conversely, failure to manage costs effectively or adapt to market changes could hinder performance. Overall, Kingfa’s strong financial position and operational efficiency present a compelling case for investors, albeit with caution advised regarding external market factors.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mitsu Chem Plast Ltd | 135 Cr. | 99.2 | 128/83.2 | 16.4 | 73.6 | 0.20 % | 10.4 % | 8.17 % | 10.0 |
| IIRM Holdings India Ltd | 578 Cr. | 84.9 | 120/68.0 | 31.5 | 21.3 | 0.00 % | 23.5 % | 18.6 % | 5.00 |
| Fiberweb (India) Ltd | 105 Cr. | 36.3 | 59.4/31.2 | 6.51 | 63.9 | 0.00 % | 10.0 % | 8.88 % | 10.0 |
| Deep Polymers Ltd | 90.1 Cr. | 37.3 | 69.9/35.0 | 18.2 | 37.5 | 0.00 % | 8.22 % | 6.10 % | 10.0 |
| DDev Plastiks Industries Ltd | 2,948 Cr. | 285 | 360/213 | 14.9 | 88.5 | 0.61 % | 33.9 % | 24.9 % | 1.00 |
| Industry Average | 1,484.75 Cr | 432.48 | 32.05 | 183.42 | 0.35% | 16.30% | 12.17% | 8.25 |
All Competitor Stocks of Kingfa Science & Technology (India) Ltd
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 351 | 340 | 366 | 339 | 351 | 394 | 404 | 416 | 418 | 440 | 470 | 462 | 466 |
| Expenses | 317 | 310 | 311 | 289 | 306 | 356 | 354 | 359 | 362 | 389 | 409 | 404 | 405 |
| Operating Profit | 34 | 31 | 55 | 50 | 45 | 38 | 51 | 57 | 56 | 51 | 60 | 58 | 61 |
| OPM % | 10% | 9% | 15% | 15% | 13% | 10% | 13% | 14% | 13% | 12% | 13% | 13% | 13% |
| Other Income | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 2 | 1 | 5 | 2 | 4 | 3 |
| Interest | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 7 |
| Profit before tax | 30 | 27 | 49 | 47 | 40 | 32 | 45 | 52 | 50 | 49 | 54 | 54 | 55 |
| Tax % | 26% | 25% | 26% | 25% | 25% | 25% | 26% | 25% | 26% | 30% | 23% | 26% | 26% |
| Net Profit | 22 | 20 | 37 | 35 | 30 | 24 | 34 | 39 | 37 | 35 | 42 | 40 | 41 |
| EPS in Rs | 18.24 | 16.70 | 30.24 | 28.93 | 24.44 | 20.09 | 27.70 | 32.26 | 30.77 | 28.60 | 34.60 | 32.86 | 30.36 |
Last Updated: December 30, 2025, 6:34 am
Below is a detailed analysis of the quarterly data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 466.00 Cr.. The value appears strong and on an upward trend. It has increased from 462.00 Cr. (Jun 2025) to 466.00 Cr., marking an increase of 4.00 Cr..
- For Expenses, as of Sep 2025, the value is 405.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 404.00 Cr. (Jun 2025) to 405.00 Cr., marking an increase of 1.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Jun 2025) to 61.00 Cr., marking an increase of 3.00 Cr..
- For OPM %, as of Sep 2025, the value is 13.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 13.00%.
- For Other Income, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Jun 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Jun 2025) to 55.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
- For Net Profit, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Jun 2025) to 41.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 30.36. The value appears to be declining and may need further review. It has decreased from 32.86 (Jun 2025) to 30.36, marking a decrease of 2.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:05 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 178 | 219 | 314 | 427 | 602 | 702 | 742 | 627 | 1,048 | 1,404 | 1,488 | 1,745 | 1,838 |
| Expenses | 181 | 212 | 288 | 408 | 560 | 666 | 698 | 607 | 966 | 1,276 | 1,303 | 1,520 | 1,607 |
| Operating Profit | -3 | 6 | 27 | 19 | 41 | 35 | 43 | 20 | 82 | 128 | 185 | 225 | 230 |
| OPM % | -2% | 3% | 8% | 5% | 7% | 5% | 6% | 3% | 8% | 9% | 12% | 13% | 13% |
| Other Income | 0 | 0 | 1 | 4 | 6 | 4 | 3 | 6 | -22 | 2 | 3 | 9 | 13 |
| Interest | 7 | 8 | 7 | 2 | 2 | 2 | 4 | 3 | 5 | 7 | 6 | 7 | 6 |
| Depreciation | 3 | 3 | 3 | 3 | 6 | 8 | 9 | 11 | 13 | 14 | 18 | 22 | 25 |
| Profit before tax | -12 | -5 | 17 | 18 | 39 | 29 | 33 | 12 | 41 | 110 | 164 | 206 | 213 |
| Tax % | -31% | -35% | 38% | 30% | 36% | 35% | 26% | 55% | 26% | 26% | 25% | 26% | |
| Net Profit | -8 | -3 | 11 | 12 | 25 | 19 | 25 | 5 | 31 | 81 | 123 | 153 | 157 |
| EPS in Rs | -6.95 | -2.49 | 8.93 | 10.24 | 20.35 | 15.74 | 20.33 | 4.39 | 25.29 | 67.22 | 101.17 | 126.22 | 126.42 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 10% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 62.50% | 466.67% | 9.09% | 108.33% | -24.00% | 31.58% | -80.00% | 520.00% | 161.29% | 51.85% | 24.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.17% | -457.58% | 99.24% | -132.33% | 55.58% | -111.58% | 600.00% | -358.71% | -109.44% | -27.46% |
Kingfa Science & Technology (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 48% |
| 5 Years: | 44% |
| 3 Years: | 48% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 56% |
| 3 Years: | 51% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | 22% |
| Last Year: | 23% |
Last Updated: September 5, 2025, 9:05 am
Balance Sheet
Last Updated: December 4, 2025, 1:32 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 10 | 10 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 |
| Reserves | 5 | 2 | 109 | 234 | 293 | 312 | 336 | 342 | 372 | 454 | 576 | 716 | 1,281 |
| Borrowings | 62 | 75 | 16 | 42 | 21 | 17 | 46 | 71 | 46 | 42 | 33 | 43 | 19 |
| Other Liabilities | 31 | 41 | 95 | 119 | 159 | 210 | 202 | 246 | 449 | 502 | 373 | 384 | 421 |
| Total Liabilities | 105 | 125 | 230 | 405 | 485 | 551 | 596 | 671 | 880 | 1,010 | 994 | 1,156 | 1,735 |
| Fixed Assets | 24 | 25 | 29 | 76 | 88 | 85 | 107 | 129 | 126 | 123 | 252 | 244 | 290 |
| CWIP | 0 | 1 | 41 | 10 | 2 | 79 | 115 | 123 | 127 | 131 | 2 | 41 | 45 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 81 | 99 | 160 | 319 | 395 | 388 | 375 | 419 | 627 | 756 | 740 | 871 | 1,399 |
| Total Assets | 105 | 125 | 230 | 405 | 485 | 551 | 596 | 671 | 880 | 1,010 | 994 | 1,156 | 1,735 |
Below is a detailed analysis of the balance sheet data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,281.00 Cr.. The value appears strong and on an upward trend. It has increased from 716.00 Cr. (Mar 2025) to 1,281.00 Cr., marking an increase of 565.00 Cr..
- For Borrowings, as of Sep 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 43.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 24.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 421.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 384.00 Cr. (Mar 2025) to 421.00 Cr., marking an increase of 37.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,735.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,156.00 Cr. (Mar 2025) to 1,735.00 Cr., marking an increase of 579.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 290.00 Cr.. The value appears strong and on an upward trend. It has increased from 244.00 Cr. (Mar 2025) to 290.00 Cr., marking an increase of 46.00 Cr..
- For CWIP, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2025) to 45.00 Cr., marking an increase of 4.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,399.00 Cr.. The value appears strong and on an upward trend. It has increased from 871.00 Cr. (Mar 2025) to 1,399.00 Cr., marking an increase of 528.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,735.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,156.00 Cr. (Mar 2025) to 1,735.00 Cr., marking an increase of 579.00 Cr..
Notably, the Reserves (1,281.00 Cr.) exceed the Borrowings (19.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -65.00 | -69.00 | 11.00 | -23.00 | 20.00 | 18.00 | -3.00 | -51.00 | 36.00 | 86.00 | 152.00 | 182.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 97 | 93 | 99 | 111 | 110 | 109 | 97 | 123 | 99 | 93 | 99 | 93 |
| Inventory Days | 54 | 64 | 85 | 69 | 85 | 63 | 67 | 100 | 110 | 94 | 76 | 82 |
| Days Payable | 66 | 72 | 127 | 108 | 108 | 119 | 115 | 152 | 181 | 155 | 110 | 94 |
| Cash Conversion Cycle | 85 | 85 | 57 | 72 | 86 | 53 | 49 | 71 | 28 | 32 | 66 | 80 |
| Working Capital Days | -7 | -14 | 66 | 59 | 96 | 59 | 55 | 57 | 39 | 45 | 78 | 85 |
| ROCE % | -9% | 4% | 22% | 9% | 13% | 9% | 10% | 4% | 16% | 25% | 30% | 31% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Conservative Hybrid Fund | 357,348 | 1.57 | 154.97 | N/A | N/A | N/A |
| SBI Flexicap Fund | 345,821 | 0.63 | 149.98 | N/A | N/A | N/A |
| SBI Automotive Opportunities Fund | 184,438 | 1.49 | 79.99 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| Diluted EPS (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| Cash EPS (Rs.) | 144.15 | 116.35 | 78.90 | 36.00 | 13.31 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 601.63 | 486.00 | 384.78 | 317.57 | 292.29 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 601.63 | 486.00 | 384.78 | 317.57 | 292.29 |
| Dividend / Share (Rs.) | 10.00 | 10.00 | 0.00 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 1440.64 | 1228.45 | 1159.08 | 865.13 | 517.93 |
| PBDIT / Share (Rs.) | 193.59 | 155.39 | 107.56 | 68.41 | 21.43 |
| PBIT / Share (Rs.) | 175.66 | 140.21 | 95.89 | 57.70 | 12.52 |
| PBT / Share (Rs.) | 170.16 | 135.58 | 90.49 | 34.14 | 9.79 |
| Net Profit / Share (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| PBDIT Margin (%) | 13.43 | 12.64 | 9.27 | 7.90 | 4.13 |
| PBIT Margin (%) | 12.19 | 11.41 | 8.27 | 6.66 | 2.41 |
| PBT Margin (%) | 11.81 | 11.03 | 7.80 | 3.94 | 1.88 |
| Net Profit Margin (%) | 8.76 | 8.23 | 5.79 | 2.92 | 0.84 |
| Return on Networth / Equity (%) | 20.97 | 20.81 | 17.47 | 7.96 | 1.50 |
| Return on Capital Employeed (%) | 29.00 | 28.66 | 24.65 | 17.08 | 3.92 |
| Return On Assets (%) | 13.22 | 12.32 | 8.05 | 3.49 | 0.79 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.04 | 0.06 |
| Total Debt / Equity (X) | 0.05 | 0.05 | 0.08 | 0.10 | 0.11 |
| Asset Turnover Ratio (%) | 1.62 | 1.48 | 1.49 | 1.35 | 0.98 |
| Current Ratio (X) | 2.02 | 1.80 | 1.37 | 1.30 | 1.45 |
| Quick Ratio (X) | 1.31 | 1.20 | 0.83 | 0.74 | 0.94 |
| Inventory Turnover Ratio (X) | 6.42 | 4.11 | 3.84 | 4.47 | 4.03 |
| Dividend Payout Ratio (NP) (%) | 7.92 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 92.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 35.23 | 33.55 | 19.95 | 15.67 | 7.84 |
| Interest Coverage Ratio (Post Tax) (X) | 23.97 | 22.84 | 13.47 | 11.19 | 2.61 |
| Enterprise Value (Cr.) | 3600.92 | 2398.91 | 1621.01 | 1546.18 | 724.65 |
| EV / Net Operating Revenue (X) | 2.06 | 1.61 | 1.15 | 1.48 | 1.16 |
| EV / EBITDA (X) | 15.36 | 12.75 | 12.44 | 18.66 | 27.92 |
| MarketCap / Net Operating Revenue (X) | 2.06 | 1.60 | 1.14 | 1.46 | 1.13 |
| Retention Ratios (%) | 92.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 4.92 | 4.03 | 3.45 | 3.99 | 2.00 |
| Price / Net Operating Revenue (X) | 2.06 | 1.60 | 1.14 | 1.46 | 1.13 |
| EarningsYield | 0.04 | 0.05 | 0.05 | 0.01 | 0.01 |
After reviewing the key financial ratios for Kingfa Science & Technology (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 144.15. This value is within the healthy range. It has increased from 116.35 (Mar 24) to 144.15, marking an increase of 27.80.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 601.63. It has increased from 486.00 (Mar 24) to 601.63, marking an increase of 115.63.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 601.63. It has increased from 486.00 (Mar 24) to 601.63, marking an increase of 115.63.
- For Dividend / Share (Rs.), as of Mar 25, the value is 10.00. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,440.64. It has increased from 1,228.45 (Mar 24) to 1,440.64, marking an increase of 212.19.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 193.59. This value is within the healthy range. It has increased from 155.39 (Mar 24) to 193.59, marking an increase of 38.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 175.66. This value is within the healthy range. It has increased from 140.21 (Mar 24) to 175.66, marking an increase of 35.45.
- For PBT / Share (Rs.), as of Mar 25, the value is 170.16. This value is within the healthy range. It has increased from 135.58 (Mar 24) to 170.16, marking an increase of 34.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For PBDIT Margin (%), as of Mar 25, the value is 13.43. This value is within the healthy range. It has increased from 12.64 (Mar 24) to 13.43, marking an increase of 0.79.
- For PBIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.41 (Mar 24) to 12.19, marking an increase of 0.78.
- For PBT Margin (%), as of Mar 25, the value is 11.81. This value is within the healthy range. It has increased from 11.03 (Mar 24) to 11.81, marking an increase of 0.78.
- For Net Profit Margin (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has increased from 8.23 (Mar 24) to 8.76, marking an increase of 0.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 20.97. This value is within the healthy range. It has increased from 20.81 (Mar 24) to 20.97, marking an increase of 0.16.
- For Return on Capital Employeed (%), as of Mar 25, the value is 29.00. This value is within the healthy range. It has increased from 28.66 (Mar 24) to 29.00, marking an increase of 0.34.
- For Return On Assets (%), as of Mar 25, the value is 13.22. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 13.22, marking an increase of 0.90.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.05. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.62. It has increased from 1.48 (Mar 24) to 1.62, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.02. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 2.02, marking an increase of 0.22.
- For Quick Ratio (X), as of Mar 25, the value is 1.31. This value is within the healthy range. It has increased from 1.20 (Mar 24) to 1.31, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.42. This value is within the healthy range. It has increased from 4.11 (Mar 24) to 6.42, marking an increase of 2.31.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.92. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 7.92, marking an increase of 7.92.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.93. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 6.93, marking an increase of 6.93.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.08. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 92.08, marking an increase of 92.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.07. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 93.07, marking an increase of 93.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.23. This value is within the healthy range. It has increased from 33.55 (Mar 24) to 35.23, marking an increase of 1.68.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.97. This value is within the healthy range. It has increased from 22.84 (Mar 24) to 23.97, marking an increase of 1.13.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,600.92. It has increased from 2,398.91 (Mar 24) to 3,600.92, marking an increase of 1,202.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 2.06, marking an increase of 0.45.
- For EV / EBITDA (X), as of Mar 25, the value is 15.36. This value exceeds the healthy maximum of 15. It has increased from 12.75 (Mar 24) to 15.36, marking an increase of 2.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.06, marking an increase of 0.46.
- For Retention Ratios (%), as of Mar 25, the value is 92.07. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 92.07, marking an increase of 92.07.
- For Price / BV (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has increased from 4.03 (Mar 24) to 4.92, marking an increase of 0.89.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.06, marking an increase of 0.46.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kingfa Science & Technology (India) Ltd:
- Net Profit Margin: 8.76%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 29% (Industry Average ROCE: 16.3%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 20.97% (Industry Average ROE: 12.17%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 35.5 (Industry average Stock P/E: 32.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.76%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Plastics - Plastic & Plastic Products | Dhun Building, 3rd Floor, Chennai (Madras) Tamil Nadu 600002 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bo Jingen | Managing Director |
| Mr. Doraiswami Balaji | Executive Director |
| Mr. Sun Yajie | Executive Director |
| Ms. Nilima Ramrao Shinde | Ind. Non-Executive Director |
| Mr. S K Subramanyan | Ind. Non-Executive Director |
| Mr. Ramachandran Sudhinder | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Kingfa Science & Technology (India) Ltd?
Kingfa Science & Technology (India) Ltd's intrinsic value (as of 29 January 2026) is ₹8854.89 which is 112.81% higher the current market price of ₹4,161.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹5,586 Cr. market cap, FY2025-2026 high/low of ₹4,987/2,451, reserves of ₹1,281 Cr, and liabilities of ₹1,735 Cr.
What is the Market Cap of Kingfa Science & Technology (India) Ltd?
The Market Cap of Kingfa Science & Technology (India) Ltd is 5,586 Cr..
What is the current Stock Price of Kingfa Science & Technology (India) Ltd as on 29 January 2026?
The current stock price of Kingfa Science & Technology (India) Ltd as on 29 January 2026 is ₹4,161.
What is the High / Low of Kingfa Science & Technology (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kingfa Science & Technology (India) Ltd stocks is ₹4,987/2,451.
What is the Stock P/E of Kingfa Science & Technology (India) Ltd?
The Stock P/E of Kingfa Science & Technology (India) Ltd is 35.5.
What is the Book Value of Kingfa Science & Technology (India) Ltd?
The Book Value of Kingfa Science & Technology (India) Ltd is 955.
What is the Dividend Yield of Kingfa Science & Technology (India) Ltd?
The Dividend Yield of Kingfa Science & Technology (India) Ltd is 0.00 %.
What is the ROCE of Kingfa Science & Technology (India) Ltd?
The ROCE of Kingfa Science & Technology (India) Ltd is 30.6 %.
What is the ROE of Kingfa Science & Technology (India) Ltd?
The ROE of Kingfa Science & Technology (India) Ltd is 23.2 %.
What is the Face Value of Kingfa Science & Technology (India) Ltd?
The Face Value of Kingfa Science & Technology (India) Ltd is 10.0.